Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

Key Takeaways A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its ...

The candidate, named KT-621, is being positioned as a potential oral competitor to Sanofi and Regeneron's blockbuster ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition ...